News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
614,678 Results
Type
Article (44407)
Company Profile (172)
Press Release (570099)
Multimedia
Podcasts (52)
Webinars (12)
Section
Business (174148)
Career Advice (2564)
Deals (31541)
Drug Delivery (105)
Drug Development (75329)
Employer Resources (153)
FDA (14325)
Job Trends (13775)
News (301737)
Policy (29231)
Tag
2024 BioCapital Digital (5)
2024 BioForest Digital (5)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (6)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (13)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (6)
2024 Genetown Digital (1)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (3)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 Lone Star Bio Digital (2)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (2743)
Academic (1)
Accelerated approval (5)
Adcomms (26)
Allergies (80)
Alliances (46184)
ALS (92)
Alzheimer's disease (1431)
Antibody-drug conjugate (ADC) (134)
Approvals (14315)
Artificial intelligence (262)
Autoimmune disease (23)
Automation (16)
Bankruptcy (329)
Best Places to Work (11185)
BIOSECURE Act (17)
Biosimilars (96)
Biotechnology (123)
Bladder cancer (77)
Brain cancer (26)
Breast cancer (268)
Cancer (2159)
Cardiovascular disease (184)
Career advice (2159)
Career pathing (32)
CAR-T (144)
Cell therapy (402)
Cervical cancer (17)
Clinical research (61178)
Collaboration (820)
Compensation (429)
Complete response letters (23)
COVID-19 (2538)
CRISPR (42)
C-suite (244)
Cystic fibrosis (91)
Data (2087)
Decentralized trials (2)
Denatured (10)
Depression (49)
Diabetes (256)
Diagnostics (6269)
Digital health (16)
Diversity (7)
Diversity, equity & inclusion (40)
Drug discovery (128)
Drug pricing (106)
Drug shortages (24)
Duchenne muscular dystrophy (91)
Earnings (62030)
Editorial (39)
Employer branding (19)
Employer resources (137)
Events (87891)
Executive appointments (732)
FDA (15486)
Featured Employer (39)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (703)
Gene editing (102)
Generative AI (24)
Gene therapy (297)
GLP-1 (724)
Government (4432)
Grass and pollen (6)
Guidances (51)
Healthcare (18162)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (124)
Indications (29)
Infectious disease (2686)
Inflammatory bowel disease (134)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (90)
Interviews (535)
IPO (14316)
IRA (46)
Job creations (3014)
Job search strategy (1774)
Kidney cancer (11)
Labor market (23)
Layoffs (443)
Leadership (21)
Legal (6422)
Liver cancer (74)
Lung cancer (315)
Lymphoma (142)
Machine learning (6)
Management (56)
Manufacturing (290)
MASH (73)
Medical device (11775)
Medtech (11779)
Mergers & acquisitions (17760)
Metabolic disorders (672)
Multiple sclerosis (74)
NASH (23)
Neurodegenerative disease (96)
Neuropsychiatric disorders (31)
Neuroscience (1968)
NextGen: Class of 2025 (6439)
Non-profit (4568)
Northern California (2360)
Now hiring (33)
Obesity (352)
Opinion (222)
Ovarian cancer (72)
Pain (82)
Pancreatic cancer (80)
Parkinson's disease (150)
Partnered (19)
Patents (217)
Patient recruitment (100)
Peanut (44)
People (55592)
Pharmaceutical (35)
Pharmacy benefit managers (13)
Phase I (18980)
Phase II (26916)
Phase III (20336)
Pipeline (1133)
Policy (141)
Postmarket research (2382)
Preclinical (7979)
Press Release (70)
Prostate cancer (96)
Psychedelics (37)
Radiopharmaceuticals (235)
Rare diseases (372)
Real estate (5392)
Recruiting (60)
Regulatory (20421)
Reports (25)
Research institute (2416)
Resumes & cover letters (378)
Rett syndrome (4)
RNA editing (3)
RSV (41)
Schizophrenia (74)
Series A (122)
Series B (77)
Service/supplier (16)
Sickle cell disease (55)
Southern California (2030)
Special edition (12)
Spinal muscular atrophy (151)
Sponsored (31)
Startups (3159)
State (2)
Stomach cancer (14)
Supply chain (66)
Tariffs (28)
The Weekly (41)
United States (20487)
Vaccines (656)
Venture capitalists (37)
Weight loss (237)
Women's health (27)
Worklife (17)
Date
Today (72)
Last 7 days (667)
Last 30 days (2190)
Last 365 days (30773)
2025 (9387)
2024 (33036)
2023 (37319)
2022 (48112)
2021 (52125)
2020 (51016)
2019 (44974)
2018 (34162)
2017 (30176)
2016 (29044)
2015 (33768)
2014 (25622)
2013 (21303)
2012 (22836)
2011 (23897)
2010 (21428)
Location
Africa (793)
Alabama (51)
Alaska (5)
Arizona (163)
Arkansas (13)
Asia (36817)
Australia (7301)
California (5357)
Canada (1860)
China (485)
Colorado (244)
Connecticut (256)
Delaware (140)
Europe (84528)
Florida (832)
Georgia (178)
Hawaii (1)
Idaho (54)
Illinois (501)
India (25)
Indiana (294)
Iowa (9)
Japan (156)
Kansas (94)
Kentucky (23)
Louisiana (12)
Maine (61)
Maryland (826)
Massachusetts (3913)
Michigan (210)
Minnesota (307)
Mississippi (2)
Missouri (86)
Montana (25)
Nebraska (22)
Nevada (61)
New Hampshire (63)
New Jersey (1550)
New Mexico (28)
New York (1537)
North Carolina (927)
North Dakota (6)
Northern California (2360)
Ohio (194)
Oklahoma (11)
Oregon (28)
Pennsylvania (1183)
Puerto Rico (12)
Rhode Island (28)
South America (1099)
South Carolina (19)
South Dakota (1)
Southern California (2030)
Tennessee (95)
Texas (798)
Utah (174)
Virginia (137)
Washington D.C. (55)
Washington State (501)
West Virginia (3)
Wisconsin (50)
614,678 Results for "sygnature discovery formerly known as sygnature chemical services".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
Drug Development
Sygnature Discovery Adopts OpenEye Scientific’s Orion™ Platform to Strengthen Molecular Design Services
OpenEye Scientific and Sygnature Discovery – a world-leading integrated discovery and pre-clinical solutions provider – today announced the adoption of OpenEye’s Orion™ platform to power Sygnature’s computational efforts in molecular design drug discovery solutions.
January 21, 2021
·
4 min read
Press Releases
Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025
March 27, 2025
·
3 min read
Press Releases
Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders
December 26, 2024
·
1 min read
Press Releases
Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platform
October 28, 2024
·
3 min read
Press Releases
Key Brain Chemical Can “Pause” Pregnancy After Conception
March 6, 2025
·
5 min read
Deals
Genentech Offers up to $765M in Biobucks to Repertoire for I&I Drug Discovery
Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new targets for an undisclosed autoimmune disorder.
April 23, 2025
·
1 min read
·
Dan Samorodnitsky
Biotech Bay
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
Nurix Therapeutics, Inc. (Nasdaq: NRIX) today disclosed the discovery and structure of NX-1607 in the First Time Disclosures session at the American Chemical Society Spring 2024 meeting in New Orleans, LA.
March 20, 2024
·
6 min read
Business
Sygnature Discovery strengthens DMPK team
Sygnature Discovery has further strengthened its DMPK (drug metabolism and pharmacokinetics) capabilities, with the addition of new senior scientists to the management team.
January 17, 2020
·
2 min read
1 of 61,468
Next
